Council of Scientific and Industrial Research

Nicholas Piramal India Limited

Satyawan Singh

Sudhir Srivastava

Anil Kumar Dwivedi

Ram Pratap

Raghwendra Pal

Sunil Kumar Puri

Anil Kumar Rastogi

Ram Chandra Gupta

Omkar Prasad Asthana

Ram Raghubir

Jagdishwar Sahai Srivastava

Shio Kumar Singh

Onkar Prasad Asthana

Vikash Chandra Pandey

Pratima Srivastava

Harsh Pati Thapliyal

Amiya Prasad Bhaduri

Guru Prasad Dutta

Sushil Kumar

Suman Preet Singh Khanuja

Rajesh Kumar

Dharam Chand Jain

Swati Ajay Piramal

Arvind Kumar Srivastava

Chandeshwar Nath

Deepak Raina

Anju Puri

Wahajul Haq

Ramesh Chandra

Guru Prakash Dutta

Madhur Ray

Sudhanshu Saxena

Hemant Kumar Singh

Nitya Nand

Nuzhat Kamal

Aseem Umesh

Sangeeta Dhawan

Renu Tripathi

Ranjendra Singh Bhakuni

Vijai Lakshmi

Jagdishwar Sahay Srivastava

Ajet Saxena

Preeti Tiwari

Madhu Khanna

Puvvada Sri Ramchandra Murthy

Mahendra Nath Srivastava

Francis Joseph Pinto

Brijendra Kumar Tripathi

Narender Tadigoppula

Dharmendra Pratap Singh

Raghavendra Pal

Nandoo Mal Khanna

Poonam Gupta

Girja Shankar

Depak Raina

Arwind Kumar Srivastava

Puvvada Sri Ramachandra Murthy

Narenda Singh

Alok Kumar Verma

Mukesh Srivastava

Amar Bahadur Singh

Himanshu Singh

A bioactive fraction obtained fromthat is useful for the treatment of diabetes and dyslipidemia. This fraction can be provided in a pharmaceutical composition that is useful as antidiabetic and antidyslipidemic agent, or can be used in a method of treating diabetes and dyslipidemia in a subject. Also, a process for the preparation of bioactive fraction from. Isomeric xyloccensins and the preparation of such compounds. Also, pharmaceutical compositions comprising a therapeutically effective amount of such isomeric xyloccensins optionally along with one or more pharmaceutically acceptable carriers, additives, lubricant and diluents and the use of such pharmaceutical compositions in a method for treating dyslipidemia.

Pharmaceutical composition for treatment of diabetes and dyslipidemia

A combination kit for the treatment of malaria caused by() having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.

Combination kit used in the treatment of malaria

The present invention provides an improved process for the preparation of Guggulsterones which comprises epoxidising 16-dihydropegnenolone acetate (16 DPA) by reacting 16DPA with hydrogen peroxide reagent adduct in the presence of a co-base in a polar solvent to obtain 3 &#x3b2; hydroxy-16 &#x3b1;, 17-oxido-5 pregnen-20-one, converting the 3 &#x3b2; hydroxy-16&#x3b1;, 17-oxido-5-pregnen-20-one by reacting with hydrazine in the presence of a strong base at refluxing temperature followed by oxidation to obtain desired guggulsterones viz. to 5, 17-(20)-cis and trans pregnadiene-3 &#x3b2;, 16-diol of the formula Ia and Ib.

Process for preparing guggulsterones

The present invention a novel use of primaquine derivative N-(3-ethylidinotetrahydrofuran-2-one)-N-(6-methoxy-8-quinolinyl)-1,4-pentanediamine in the treatment and controlling the spread of malaria. In particular, the present invention discloses a method of treatment of malaria by the use of primaquine derivative N-(3-ethylidinotetrahydrofuran-2-one)-N-(6-methoxy-8-quinolinyl)-1,4-pentanediamine as a gametocytocidal agent.

[object Object]

The present invention relates to A composition obtained from the lipid soluble extract of rhizomes and leaves ofof Zingiberaceae family, useful for the treatment of neurocerebrovascular disorders, said composition comprising fraction A consisting of ar-turmerone of formula 1, and turmerone of formula 2, and/or along with fraction B consisting of curcumene and zingiberine, and/or fraction C consisting of germacrone, curcumerone, zedoarone, sedoarondiol, isozdedoaronidiol, curcumenone, and curlone, and/or pharmaceutically acceptable additives and a method of treating neurocerebrovascular disorders in animals including humans using said composition by administering therapeutically effective amount of lipid soluble extract.

Herbal medicaments for the treatment of neurocerebrovascular disorders

The present invention provides new uses of Gugulipid, an ethyl acetate extract of the resin of the plant, for controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin and a method of preparing Gugulipid by agitating the resin in shake flask assembly or sonicating assembly and preparing a solid or a creamy dosage forms.

Method of treating a cognitive memory dysfunction using Gugulipid

The invention provides novel inclusion complexes of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin, pharmaceutical preparations containing these inclusion complexes of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin derivatives, the complexes being better soluble in water and having improved biopharmaceutical properties such as lesser toxicity, better analgesic action and non-addiction properties.

Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment

The present invention relates to a synergistic formulation comprising pharmaceutically effective amount of &agr;/&bgr; arteether and a neutralized refined vegetable oil suitable for administration by rectal route, method for the treatment of cerebral and comatose malaria and process for the preparation of the said formulation.

Synergistic anti-malarial formulation

Growing community of inventors

Lucknow, India

Satyawan Singh